NDANASALAEROSOL, METERED
Approved
Mar 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
QNASL (beclomethasone dipropionate) by Teva is anti-inflammatory activity. Approved for asthma, allergic rhinitis. First approved in 2012.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QNASL is a metered-dose nasal aerosol formulation of beclomethasone dipropionate, a corticosteroid indicated for asthma treatment. It works by rapidly converting to its active metabolite (17-BMP), which exhibits potent glucocorticoid receptor binding (~13x dexamethasone) to inhibit inflammatory cells and mediators. The drug provides favorable topical anti-inflammatory activity with minimal systemic corticosteroid effects at recommended doses.
$5.0MPart D
PeakStable
5.5 years to LOEProduct is at peak lifecycle with modest Part D utilization, suggesting a mature, stable commercial infrastructure with limited growth opportunity.
Mechanism of Action
anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Corticosteroids have been shown to have multiple anti-inflammatory effects, inhibiting both inflammatory cells (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and…
Indications (2)
Worked on QNASL at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.